Drugs / Artefenomel
Artefenomel
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT03542149 | Apr 2018 → Apr 2019 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT04069221 | Feb → May 2017 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02083406 | Jul 2014 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01958619 | Oct 2013 → Jan 2014 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01853475 | Apr → Jul 2013 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01713608 | Nov 2012 → Feb 2013 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02453581 | Sep 2012 → Mar 2013 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01660022 | Sep 2012 → May 2013 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01615822 | Aug 2012 → Apr 2013 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded |
| Phase 1 | NCT01383096 | Apr → Aug 2012 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT00928083 | Apr → Oct 2009 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02573857 | Oct 2015 → May 2016 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded |
| Phase 1/2 | NCT02431650 | Apr 2015 → Sep 2016 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/2 | NCT02389348 | Feb → Jun 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT03660839 | Sep 2018 → Nov 2019 | Plasmodium falciparum malaria | Sanofi | Completed | Missed primary |
| Phase 2 | NCT02497612 | Jul 2015 → Sep 2019 | Plasmodium falciparum malaria | Sanofi | Terminated | Missed primary |
| Phase 2 | NCT01713621 | Mar 2013 → Apr 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2 | NCT01213966 | Oct 2010 → May 2012 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02083380 | Jul 2014 → Oct 2015 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT02387580 Comparator | Apr → Jun 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01732588 Comparator | Nov → Dec 2012 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2 | NCT04264130 Comparator | Jul 2018 → Dec 2019 | urinary schistosomiasis | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | artefenomel | “To investigate in vivo gametocytocidal drug activity in this model, participants were either given an experimental antimalarial, artefenomel (500 mg), or a known...” PMID 29389671 ↗ Mar 2018 |
| Known as | OZ439 | “A single-centre Phase 1b study to assess the safety, tolerability, pharmacokinetic profile, and antimalarial activity of single doses of coadministered artefenomel (OZ439) and...” NCT03542149 ↗19“single dose combination of OZ439 (Artefenomel)/FQ (Ferroquine)” NCT02497612 ↗ “Artefenomel (OZ439)” NCT03660839 ↗ |
| Known as | OZ439 mesylate | “OZ439 mesylate 800mg Powder in Bottle for Oral Suspension” NCT01383096 ↗ |
| Modality | Small molecule | “OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent.” NCT00928083 ↗ |
| Route | Oral | “OZ439 was administered as single oral daily doses of a capsule formulation (50-1200 mg) or an oral dispersion (400-1600 mg, fed and fasted states)” PMID 22759078 ↗ Feb 2013 |